BJL
VNDA icon

Brighton Jones LLC’s Vanda Pharmaceuticals VNDA Stock Holding History

Brighton Jones LLC’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
26,085
+13,590
+109% +$88.8K ﹤0.01% 1275
2026
Q1 		$86.3K Buy
+12,495
New +$96.4K ﹤0.01% 1135

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Brighton Jones LLC's VNDA Position: Q2 2026 in Review

Brighton Jones LLC increased its Vanda Pharmaceuticals (VNDA) stake by 109% in Q2 2026, buying an estimated $88.8K and bringing the position to 26,085 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Brighton Jones LLC first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Brighton Jones LLC held 26,085 shares of Vanda Pharmaceuticals worth $160K as of Q2 2026.
  • Brighton Jones LLC bought 13,590 Vanda Pharmaceuticals shares in Q2 2026, an estimated $88.8K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1275 holding.
  • Brighton Jones LLC first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.